Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

Colin Baigent(University of Oxford), Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), Silvio E. Inzucchi(Yale University), Deepak L. Bhatt(Mount Sinai Hospital), Brendon L. Neuen(The George Institute for Global Health), Martina Brueckmann, Jennifer B. Green, Javed Butler(Jackson Memorial Hospital), John J.V. McMurray(University of Glasgow), Vlado Perkovic(New South Wales Department of Health), Natalie Staplin(University of Oxford), David Z.I. Cherney(University Health Network), Marc S. Sabatine(Brigham and Women's Hospital), Jonathan Emberson(University of Oxford), Hiddo J.L. Heerspink(University Medical Center Groningen), Christoph Wanner(Universitätsklinikum Würzburg), Finnian R. McCausland, Kenneth W. Mahaffey(Cardiovascular Institute of the South), David Preiss(Medical Research Council), Milton Packer(Baylor University Medical Center), Scott D. Solomon(Brigham and Women's Hospital), Muthiah Vaduganathan(Brigham and Women's Hospital), Kaitlin J. Mayne, David C. Wheeler(University College London), Doreen Zhu, Darren K. McGuire(Parkland Health & Hospital System), Bruce Neal(UNSW Sydney), William G. Herrington(Oxford Health NHS Foundation Trust), Martin Landray(Gentofte Hospital), Chih‐Chin Liu, Alistair Roddick, Sibylle J. Hauske(Boehringer Ingelheim (Germany)), Richard Haynes, Stephen D. Wiviott(Thrombolysis in Myocardial Infarction Study Group), Meg Jardine(Royal North Shore Hospital), Parminder K. Judge(University of Oxford), Sarah Y A Ng, Stefan D. Anker(Bayer (Germany))
The Lancet
November 1, 2022
Cited by 969


Related Papers